ALLO SCHEDULE 13G: SEC filing

Citadel entities and Kenneth Griffin

Filed with the SEC on · accession 0001104659-26-128279

ALLO filed a SCHEDULE 13G (schedule 13g) with the SEC on Nov 16, 2026. Citadel entities and Kenneth Griffin filed a Schedule 13G reporting beneficial ownership of Allogene Therapeutics common stock, with Griffin deemed to beneficially own 7.1% and various Citadel entities owning between 2.4% and 4.7%. The stock moved -3.8% by the first close after the filing.

Summary of the filing

Citadel entities and Kenneth Griffin filed a Schedule 13G reporting beneficial ownership of Allogene Therapeutics common stock, with Griffin deemed to beneficially own 7.1% and various Citadel entities owning between 2.4% and 4.7%. The filing is a passive investment disclosure with no intent to influence control.

Key details

Shares beneficially owned by Kenneth Griffin$24.7M
Shares beneficially owned by Citadel Securities Group LP and Citadel Securities GP LLC$16.4M
Shares beneficially owned by Citadel Securities LLC$14.1M
Shares beneficially owned by Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC$8.3M
IssuerAllogene Therapeutics, Inc.
Reporting personCitadel Securities GP LLC
Reporting personCitadel Securities LLC
Reporting personCitadel Securities Group LP
Reporting personCitadel Advisors LLC
Reporting personCitadel Advisors Holdings LP
Reporting personCitadel GP LLC
President and ceo of citadel gp llcKenneth Griffin
Authorized signatorySeth Levy

How ALLO stock reacted

Close before

$0.84

Nov 13, 2026

First close after

-3.78%

$0.81

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for ALLO, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ALLO?

Click here

Frequently asked questions

What did ALLO file with the SEC on Nov 16, 2026?

ALLO filed a SCHEDULE 13G (SEC filing). Citadel entities and Kenneth Griffin filed a Schedule 13G reporting beneficial ownership of Allogene Therapeutics common stock, with Griffin deemed to beneficially own 7.1% and various Citadel entities owning between 2.4% and 4.7%. The filing is a passive investment disclosure with no intent to influence control.

How do I read a SCHEDULE 13G?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).

How did ALLO stock react to this filing?

ALLO closed at $0.84 before the filing and $0.81 on Nov 16, 2026 (-3.78%).

Other ALLO SEC filings

Get alerts when ALLO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days